March 2017 – Boston Strategic Partners, Inc. co-authored article “Cost Savings from Reduced Hospitalizations with Use of Home Noninvasive Ventilation for COPD” has been published in the March 2017 Issue of Value in Health, the Journal of the International Society for Pharmacoeconomics and Outcomes Research.

Abstract

Although evidence suggests significant clinical benefits of home noninvasive ventilation (NIV) for management of severe chronic obstructive pulmonary disease (COPD), economic analyses supporting the use of this technology are lacking.

Objectives: To evaluate the economic impact of adopting home NIV, as part of a multifaceted intervention program, for severe COPD.

Methods: An economic model was developed to calculate savings associated with the use of Advanced NIV (averaged volume assured pressure support with autoexpiratory positive airway pressure; Trilogy100, Philips Respironics, Inc., Murrysville, PA) versus either no NIV or a respiratory assist device with bilevel pressure capacity in patients with severe COPD from two distinct perspectives: the hospital and the payer. The model examined hospital savings over 90 days and payer savings over 3 years. The number of patients with severe COPD eligible for home Advanced NIV was user-defined. Clinical and cost data were obtained from a quality improvement program and published reports. Scenario analyses calculated savings for hospitals and payers covering different COPD patient cohort sizes.

Results: The hospital base case (250 patients) revealed cumulative savings of $402,981 and $449,101 over 30 and 90 days, respectively, for Advanced NIV versus both comparators. For the payer base case (100,000 patients), 3-year cumulative savings with Advanced NIV were $326 million versus no NIV and $1.04 billion versus respiratory assist device.

Conclusions: This model concluded that adoption of home Advanced NIV with averaged volume assured pressure support with autoexpiratory positive airway pressure, as part of a multifaceted intervention program, presents an opportunity for hospitals to reduce COPD readmission-related costs and for payers to reduce costs associated with managing patients with severe COPD on the basis of reduced admissions.

Link to the full article: http://www.valueinhealthjournal.com/current

About BSP
Founded in 2003, Boston Strategic Partners, Inc. is a dedicated healthcare and life sciences company. We offer five different types of services:

For more information or to schedule a meeting with our team, please email us at info@bostonsp.com

 About Value in Health

Value in Health is an international, indexed journal that publishes original research and health policy articles that advance the field of pharmacoeconomics and outcomes research to help health care leaders make evidence-based decisions. The journal’s 2015 impact factor score is 3.824. Value in Health is ranked 3rd out of 74 journals in health policy and services (social sciences), 8th out of 87 journals in health care sciences and services, and 10th out of 344 journals in economics (social sciences). Value in Health is published bi-monthly and circulates to more than 10,000 readers around the world.

www.ispor.org/valueinhealth